Point Of Contact Not Available

The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting the development and licensure of botulism anti-toxin immunoglobulin (not botulinum toxin anti-immunoglobulin as stated in the June 5, 2002 notice) as a part of our Biodefense program. NIAID is interested in receiving letters from organizations that have the needed development and production capabilities. Interested organizations should submit a letter of interest that contains a detailed description of a potential development, production and marketing plan, as well as their R&D capabilities and interest. The letter of interest along with any supporting documentation shall not exceed 10 pages. Letters of interest will be kept confidential and will help in determining the need for an RFP to support further development, testing, and licensure of these products, and in assembling a potential source list for distribution if an RFP is issued. Submit responses to the attention of Barbara Shadrick at the address listed in this special notice.

Bid Protests Not Available